For further information regarding the clinical trials, please speak with your doctor or contact the Virginia Piper Cancer Institute Research Department at 612-863-8716.
Please note that while our goal is to keep this Web site as current as possible, it is possible that the status of a study may be different than what is reflected below. Please contact the Virginia Piper Cancer Institute Research Department for further information.
Tissue Microarrary for Validation of a New Immunohistochemical Panel Pitutary Adenoma
EMD 121974-011
Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter - a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC).
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
